Filgueiras, Luciano Ribeiro published the artcileLeukotriene B4 as a potential therapeutic target for the treatment of metabolic disorders, Name: [(2-Hexylcyclopentylidene)amino]thiourea, the publication is Frontiers in Immunology (2015), 515/1-515/4, database is CAplus and MEDLINE.
A review discusses the role of leukotriene B4 role in metabolic dysfunctions. By increasing MyD88 expression, LTB4 enhances macrophage response to TLR/IL1 receptor agonists potentiating the sterile inflammation, a central event in metabolic disease progression. Furthermore, LTB4 can amplify tissue injury by increasing reactive oxygen and nitrogen species that are known to mediate β-cell destruction, impairing insulin production Although further studies are required, inhibition of the LTB4/BLT1 axis is a promising therapeutic strategy for the treatment of metabolic disorders. It also discusses about the development of 5-LO inhibitor that is already approved to treat asthma, and BLT1 antagonists and reduction in LTB4 production or activity may reduce sterile inflammation and decrease disease severity.
Frontiers in Immunology published new progress about 321673-30-7. 321673-30-7 belongs to amides-buliding-blocks, auxiliary class Immunology/Inflammation,Scavenger receptor, name is [(2-Hexylcyclopentylidene)amino]thiourea, and the molecular formula is C12H23N3S, Name: [(2-Hexylcyclopentylidene)amino]thiourea.
Referemce:
https://en.wikipedia.org/wiki/Amide,
Amide – an overview | ScienceDirect Topics